AIDS Alert Archives – November 1, 2009
November 1, 2009
View Archives Issues
-
Eureka! Success of combo HIV vaccine raises hopes, should revitalize research
When news erupted in late September that a combination of two previously-failed HIV vaccines the Sanofi Pasteur's Alvac and Global Solutions for Infectious Diseases' AIDSVAX was successful with 31.2% of people vaccinated in a phase III Thailand clinical trial, a great deal changed for the HIV vaccine research world. -
Promising leads opening up with vaccine research
The recent positive news from the Thailand HIV vaccine trial comes at a good time for the field as scientists recently have discovered other interesting potential ways to prevent infection from taking hold. -
HIV baby boom: Following perinatally-infected children
HIV clinicians and investigators now have a unique opportunity to learn more about the disease as the last large group of U.S. babies infected with HIV at birth are approaching adulthood with prospects of living decades longer. -
HIV/AIDS News Update: ADAPs across nation are running out of money
AIDS Drug Assistance Programs (ADAPs) in more than a dozen states were starting waiting lists or expected to restrict antiretroviral drug access soon, according to an ADAP update in early October, 2009. -
Woman, protect thyself: New options in protection
In 2007, the Centers for Disease Control and Prevention reported that 26% of HIV/AIDS diagnoses among adolescents and adults were among females.1 What will it take to expand the number of available options for female-controlled prevention of infection? -
Abstract & Commentary: HIV primary care: You've come a long way, baby
The 2009 update of HIV primary care guidelines make several new recommendations, and the evidence basis for these is documented in the paper. The following changes are present in the 2009 guidelines: -
FDA Notifications
The Food and Drug Administration (FDA) licensed, on Sept. 18, 2009, the Abbott Prism HIV O Plus assay, a new screening tool designed to detect the presence of antibodies to the two types of the virus that causes AIDS, HIV 1 and HIV 2.